cyclin E、p53、CD44s、CD44v6与早期乳腺癌的相关性及预后预测分析

摘要/Abstract

摘要： 目的分析肿瘤组织的细胞周期素E（cyclin E）和p53、CD44s、CD44v6蛋白与早期乳腺癌的相关性及预后预测价值。方法选取2018年7月—2020年7月喀什地区第二人民医院收治的80例临床分期为Ⅰ~Ⅱ期的早期乳腺癌患者进行回顾性分析,将其分为恶性组;另选取同期喀什地区第二人民医院收治的80例通过病理学检验确诊为良性乳腺肿瘤患者,将其分为良性组。分别对两组患者留存的肿瘤组织进行免疫组化检测,检测cyclin E、p53、CD44s、CD44v6表达,并对比上述指标的阳性率,应用Spearman相关分析方法分析cyclin E、p53、CD44s、CD44v6与早期乳腺癌的相关性。所有患者均采取手术治疗,随后对80例早期乳腺癌患者进行3年随访,依照随访结果将患者分为2个亚组,即预后不良组（n=25）和预后良好组（n=55）,对比两组患者一般临床特征及cyclin E、p53、CD44s、CD44v6阳性率,并应用Logistic回归分析cyclin E、p53、CD44s、CD44v6对早期乳腺癌预后的预测价值。结果恶性组患者cyclin E、p53、CD44s、CD44v6阳性率分别为42.50%、61.25%、77.50%、81.25%,明显高于良性组1.25%、5.00%、10.00%、12.50%（P<0.05）;Spearman相关分析结果显示：cyclin E、p53、CD44s、CD44v6与早期乳腺癌呈正相关（P<0.05）;预后良好组与预后不良组患者绝经情况、年龄、病理类型、治疗方式、三阴性乳腺癌、肿瘤大小、组织分化程度对比,差异无统计学意义（P>0.05）,预后良好组与预后不良组患者临床分期、cyclin E、p53、CD44s、CD44v6阳性例数对比,差异有统计学意义（P<0.05）;Logistic回归分析结果表明：cyclin E、p53、CD44s、CD44v6阳性表达为影响早期乳腺癌预后的独立影响因素（P<0.05）。结论 cyclin E、p53、CD44s、CD44v6表达水平与乳腺癌的发生、发展具有明显关系,且上述指标呈阳性表达为早期乳腺癌预后不良的独立预测因素。

关键词: 早期乳腺癌, cyclin E, p53, CD44s, CD44v6, 免疫组化

Abstract: Objective To analyze the correlation and prognostic value of cyclin E, p53, CD44s, CD44v6 proteins in tumor tissues with early breast cancer. Methods From July 2018 to July 2020, 80 cases of early breast cancer patients with clinical stage Ⅰ-Ⅱ in our hospital were selected as the research object, and they were divided into malignant group, and another 80 cases of benign breast cancer patients treated in our hospital in the same period were selected as benign group. The expressions of cyclin E, p53, CD44s, CD44v6 in tumor tissues of the two groups were detected by immunohistochemistry, and the positive rates of the above indicators were compared. The correlation between cyclin E, p53, CD44s, CD44v6 and early breast cancer was analyzed by Spearman correlation analysis. All patients were treated with surgery, and then 80 patients with early breast cancer were followed up for 3 years. According to the follow-up results, the patients were divided into two subgroups, namely, the poor prognosis group (n=25) and the good prognosis group (n=55). The general clinical characteristics and the positive rates of cyclin E, p53, CD44s and CD44v6 in the two groups were compared, and the predictive value of cyclin E, p53, CD44s and CD44v6 for the prognosis of early breast cancer was analyzed by Logistic regression analysis. Results The positive rates of cyclin E, p53, CD44s and CD44v6 in malignant group were 42.50%, 61.25%, 77.50% and 81.25% respectively, which were significantly higher than those in benign group (1.25%, 5.00%, 10.00% and 12.50%, P<0.05); Spearman correlation analysis showed that cyclin E, p53, CD44s, CD44v6 were positively correlated with early breast cancer (P<0.05); There was no statistically significant difference in menopause, age, pathological type, tumor size and histological differentiation between the good prognosis group and the poor prognosis group (P>0.05). There was statistically significant difference in clinical stage, cyclin E, p53, CD44s, CD44v6 positive number between the good prognosis group and the poor prognosis group (P<0.05); The final Logistic regression analysis showed that the positive expression of cyclin E, p53, CD44s and CD44v6 were the independent factors influencing the prognosis of early breast cancer (P<0.05). Conclusion The expression levels of cyclin E, p53, CD44s and CD44v6 are significantly related to the occurrence and development of breast cancer, and the positive expression of these indicators is an independent predictor of poor prognosis in early breast cancer.

Key words: early breast cancer, cyclin E, p53, CD44s, CD44v6, immunohistochemistry

中图分类号:

张淑娟, 穆尼热·穆合塔尔. cyclin E、p53、CD44s、CD44v6与早期乳腺癌的相关性及预后预测分析[J]. 中华养生保健, 2024, 42(19): 51-54.

ZHANG Shu-juan, Munire Muhetaer. Correlation and Prognostic Analysis of Cyclin E, P53, CD44s, CD44v6 and Early Breast Cancer[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(19): 51-54.

参考文献

[1] KERR A J, DODWELL D, MCGALE P, et al.Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality[J].Cancer Treat Rev,2022,105:102375.
[2] REN W, CHEN M, QIAO Y, et al.Global guidelines for breast cancer screening: A systematic review[J].Breast,2022,64:85-99.
[3] 王倩,谭小军,张东辉,等.β-catenin,Cyclin D1和DKK1在乳腺癌病理辅助诊断中的应用探讨[J].国际肿瘤学杂志,2021,48(7):402-408.
[4] 王彦龙,肖兰,朱丽娜,等.不同p53表达乳腺癌临床病理特征及MRI表现对照分析[J].四川医学,2021,42(2):162-166.
[5] 梁垲,贾海全,王皓颖,等.乳腺癌组织中E-cadherin表达与CD44V6及N-cadherin表达相关性研究[J].医学理论与实践,2022,35(15):2646-2649.
[6] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,25(9):63.
[7] 刘润奇,叶建森,徐天鸣,等.乳腺癌Ki-67和CyclinD1在预测及评估新辅助化疗疗效中的价值[J].西部医学,2022,34(5):753-756,760.
[8] 钟明浩,杨志企,姚纯,等.定量DCE-MRI参数,ADC值与乳腺癌p53,CK56表达状态相关性研究[J].国际医学放射学杂志,2021,44(4):403-407.
[9] 姚淑晖,张静,刘玉梅,等.三阴乳腺癌新辅助化疗前后CD44v6的表达及临床意义[J].中国煤炭工业医学杂志,2022,25(2):162-166.
[10] 陈功泉,石琳,胡卯秀,等.三阴性乳腺癌的超声图像特征及其与P53,BRCA1蛋白表达的相关性[J].临床超声医学杂志,2021,23(6):406-409.
[11] KANADYS W, BARAŃSKA A, MALM M, et al. Use of Oral Contraceptives as a Potential Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis of Case-Control Studies Up to 2010[J].Int J Environ Res Public Health,2021,18(9):4638.
[12] 朱成斌,茅芯慧,王珍.PD1及PDL1在乳腺癌中的表达变化及其与患者临床病理参数和预后的关系[J].临床和实验医学杂志,2022,21(18):1957-1960.
[13] 张瑞娟. CD44表达对乳腺癌干细胞的影响[J].中国生物制品学杂志,2021,34(11):1387-1390,1396.
[14] RAFN B S, CHRISTENSEN J, LARSEN A, et al.Prospective Surveillance for Breast Cancer-Related Arm Lymphedema: A Systematic Review and Meta-Analysis[J].J Clin Oncol,2022,40(9):1009-1026.
[15] 戴睿,林萍,宋精玲,等.miR-541-3p靶向SPOCD1基因通过Wnt/β-catenin信号通路抑制乳腺癌细胞增殖,迁移和侵袭[J].中国免疫学杂志,2021,37(6):694-699.
[16] 张瑾晖,王丹,姜珏王,等.非特殊型浸润性乳腺癌声像图特征与P53表达的相关性分析[J].中国超声医学杂志,2021,37(8):862-865.